Skip to main content

Table 1 Comparison between adults and children with viridans streptococcal bacteremia during febrile neutropenia

From: Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children

Factor

Adults (≥ 20 years old) (n=141)

Children (< 20 years old) (n=61)

p-value

Age (years)

44 (36-54)

9 (3-15)

 

Gender (male)

67 (47.5)

41 (67.2)

0.010

Underlying disease

  

0.215

 Acute myeloid leukemia

103 (73.1)

44 (72.1)

 

 Acute lymphoblastic leukemia

23 (16.3)

13 (21.3)

 

 Other leukemias

4 (2.8)

3 (4.9)

 

 Non-Hodgkin lymphoma

8 (5.7)

1 (1.6)

 

 Multiple myeloma

3 (2.1)

0 (0.0)

 

Complete remission status

84 (59.6)

40 (65.6)

0.421

Preceding therapy

  

0.103

 Conventional chemotherapy

131 (92.9)

61 (100.0)

 

 Hematopoietic cell transplantation

   

   Autologous

8 (5.7)

0 (0.0)

 

   Allogeneic

2 (1.4)

0 (0.0)

 

Duration after the preceding therapy (days)

12 (10-13)

13 (12-14)

<0.001

Antibacterial prophylaxis*

  

< 0.001

 None

4 (2.9)

1 (1.6)

 

 Trimethoprim/sulfamethoxazole

0 (0)

53 (86.9)

 

 Ciprofloxacin

134 (97.1)

7 (11.5)

 

Accompanying symptoms

   

 Oral mucositis

36 (25.5)

5 (8.2)

0.005

 Cough

9 (6.4)

12 (19.7)

0.004

 Sputum

5 (3.5)

4 (6.6)

0.458

 Rhinorrhea

1 (0.7)

0 (0.0)

1.000

 Diarrhea

46 (32.6)

14 (23.0)

0.167

 Abdominal pain

35 (24.8)

3 (4.9)

0.001

Polymicrobial infection

   

 Other bacterial infection

18 (12.8)

4 (6.6)

0.193

 Fungal infection

16 (11.3)

2 (3.3)

0.065

Complications attributable to VSB

22 (15.6)

4 (6.6)

0.078

 Ventilator care

5 (3.5)

3 (4.9)

0.700

 Acute respiratory distress syndrome

4 (2.8)

2 (3.3)

1.000

 Shock

22 (15.6)

4 (76.6)

0.078

 Death

3 (2.1)

1 (1.6)

1.000

Overall death

12 (8.5)

2 (3.3)

0.236

Laboratory findings

   

  White blood cell count (/μL)

50 (20-160)

60 (30-135)

0.127

  Absolute neutrophil count (/μL)

0 (0-0)

0 (0-0)

0.228

  Duration of neutropenia before the diagnosis of VSB (days)

6 (4-7)

6 (4-8)

0.138

  Total duration of neutropenia (days)

17 (12-24)

15 (11-22)

0.823

 Peak C-reactive protein level (mg/dL)

19.6 (13.2-26.5)

18.6 (9.7-25.5)

0.157

  1. Data are median (inter quartile range) or No. (%) of cases.
  2. VSB viridans streptococcal bacteremia.
  3. *Antibacterial prophylaxis was evaluated in 199 patients (138 adults, 61 children) except 3 adults who had been undergoing ceftazidime treatment.